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Abstract The chemokine CXCL12/SDF-1 and its
receptors CXCR4 and CXCR7 play a major role in tumor
invasion, proliferation and metastasis. Since both receptors
are overexpressed on distinct tumor cells and on the tumor
vasculature, we evaluated their potential as targets for
detection of cancers by molecular imaging. We synthesized
conjugates of CXCL12 and the near-infrared (NIR) ﬂuo-
rescent dye IRDye
800CW, tested their selectivity, sensi-
tivity and biological activity in vitro and their feasibility to
visualize tumors in vivo. Puriﬁed CXCL12-conjugates
detected in vitro as low as 500 A764 human glioma cells or
MCF-7 breast cancer cells that express CXCR7 alone or
together with CXCR4. Binding was time- and concentra-
tion-dependent, and the label could be competitively dis-
placed by the native peptide. Control conjugates with
bovine serum albumin or lactalbumin failed to label the
cells. In mice, the conjugate distributed rapidly. After
1–92 h, subcutaneous tumors of human MCF-7 and A764
cells in immunodeﬁcient mice were detected with high
sensitivity. Background was observed in particular in liver
within the ﬁrst 24 h, but also skull and hind limbs yielded
some background. Overall, ﬂuorescent CXCL12-conju-
gates are sensitive and selective probes to detect solid and
metastatic tumors by targeting tumor cells and tumor
vasculature.
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Abbreviations
CXCL11 or I-TAC Interferon-inducible T cell a
chemoattractant
CXCL12 or SDF-1 Stromal cell-derived factor-1
EGF Epidermal growth factor
RT-PCR Reverse transcription polymerase
chain reaction
Introduction
Diagnosis of cancer, cancer metastasis, precision of sur-
gical resection, monitoring of therapy in preclinical models
or in the clinical situation could be greatly improved by
effective and simple imaging methods. Optical imaging
methods with tumor-targeting molecular probes ﬂuorescent
in the near-infrared (NIR) range (emission/excitation
650–900 nm) have the advantage that they allow not only
surface, but deeper imaging up to few cm into the tissue
[1], show a high sensitivity and require comparably simple
instrumentation. Tumor-selective or -elevated cell surface
molecules such as receptors or adhesion proteins are the
predominant targets for NIR-conjugates with antibodies [2]
or ligands [3, 4]. As a novel approach, we developed and
evaluated bioconjugates of chemokines with NIR ﬂuores-
cent dyes to enable sensitive detection of tumor cells/tumor
endothelial cells.
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DOI 10.1007/s10585-011-9403-yChemokines, small (8–15 kDa) chemotactic cytokines,
and their receptors play a critical role in tumor initiation,
promotion, progression and metastasis [5]. The chemokine
SDF-1 (stromal cell-derived factor-1, CXCL12) appears to
be of particular importance in tumor biology, especially in
tumor metastasis, invasion and angiogenesis. Interaction of
SDF-1 with its receptor CXCR4 (also called fusin) that is
expressed on some tumor cells directs them to peripheral
tissues like lung, liver, lymph nodes or bone marrow where
the ligand is constitutively expressed [6]. Furthermore, the
SDF-1–CXCR4 axis promotes paracrine tumor growth,
enhances tumor cell invasiveness, induces tumor angio-
genesis and attracts leukocytes [7, 8]. Recently, a novel
receptor for SDF-1 has been identiﬁed, termed CXCR7/
RDC1 [9, 10], that binds in addition to SDF-1, I-TAC
(interferon-inducible T cell a chemoattractant, CXCL11)
but with tenfold lower afﬁnity. As with CXCR4, CXCR7 is
found on tumor and tumor-endothelial cells. CXCR7 is
particularly highly expressed on breast, lung, prostate
cancer and glioma cells [10–14]. Thus, a ﬂuorescent SDF-
1-derivative would target tumors at several sites: the tumor
vasculature and the tumor cells via CXCR4 and CXCR7.
Experimental procedures
Peptides, dyes and cells
Recombinant human SDF-1a (CXCL12), CXCL16 and
epidermal growth factor (EGF) were obtained from Prep-
rotech, London, UK, other proteins from Sigma, St. Louis,
MO, USA. Dipeptidyl peptidase IV (DPP IV)-truncated
CXCL12 was prepared and puriﬁed as described for
CXCL11 [15]. IRDye
800CW-N-hydroxysuccinimide
(NHS) ester was purchased from LI-COR, Lincoln, NE,
USA. IntegriSense 680
 which binds to the integrins
aVb3/aVb5 was purchased from VisenMedical (MA,
USA). A764 glioma cell lines were obtained from a sur-
gical tumor by dissociation and cultivation in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Invitrogen, Carlsbad,
CA, USA) plus 10% FCS [16], preparation and culture of
other cell types have been described elsewhere [14, 17].
Peptide conjugation and puriﬁcation
Peptides (1 nmol) were incubated in 50 ll 0.1 M Na2CO3-
buffer, pH 8.6, with 5 nmol IRDye
800CW-N-hydroxy-
succinimide ester dissolved in 5 ll dimethyl sulfoxide for
2 h at room temperature in the dark. Excess reactive groups
were saturated by addition of 2 ll 1 M Tris–HCl buffer,
pH 8.6, and incubation for additional 15 min. Then, con-
jugates were separated either by application on Sephadex
G25 spin columns (GE Healthcare, Buckinghamshire, UK)
and elution with 250 ll 0.14 M NaCl in 20 mM Hepes
buffer, pH 7.4, under centrifugation (2 min, 10009g) or
(CXCL12-conjugate) by application on a Superdex Peptide
3.2/30 gel chromatography column (GE Healthcare)
equilibrated and eluted with the above buffer. Fractions
containing bound dye to peptide were combined and used
for the experiments. Similar conjugations were made with a
Cy3 NHS ester (GE Healthcare) to yield corresponding
Cy3-conjugates.
Quantitative RT-PCR, analysis of kinase
phosphorylation and other biological assays
For quantitative RT-PCR, RNA was isolated with the
TRIZOL reagent, digested by DNase, cDNA synthesized
and real time RT-PCR was performed [14] using TaqMan
primer probes (Applied Biosystems, Foster City, CA,
USA): hGAPDH (Hs99999905_m1), hCXCR4 (Hs00607
978_s1), hCXCR7 (Hs00664172_s1). Cycles of threshold
(CT) were determined with a ABI PRISM 7000 sequence
detection system, and DCT values = CTGene of interest-
CTGAPDH were calculated. A DCT value of 3.3 corre-
sponds to one magnitude lower gene expression compared
to GAPDH.
For kinase phosphorylation analysis, cells (70% con-
ﬂuent) were washed twice with serum-free DMEM con-
taining 1% (bovine serum albumin) BSA (each 1 h) before
stimulation that was done in fresh serum-free medium with
1% BSA. Stimulated cells were washed twice with ice-cold
phosphate-buffered saline, lysed with Triton-lysis-buffer,
lysates with equal amounts of proteins were separated by
SDS-PAGE (10%), blotted onto polyvinylidene diﬂuoride
membranes that were probed with anti-pErk1/2 (Thr202/
Tyr204; 1:500; Cell Signaling Technology, Danvers, MA,
USA) and re-probed after stripping with methanol and
0.1 mol/l glycine/HCl buffer, pH 2.5, with anti-Erk2
(1:500; Santa Cruz) using horseradish peroxidase-labeled
anti-rabbit IgG (1:20,000; DAKO) and enhanced chemi-
luminescence visualization (ECL Advance
TM
; GE Health-
care) as described [18].
Binding experiments
Cells cultivated for 24 h at different densities in 24-well
plates were incubated in serum-free medium with NIR-
conjugates for the times and concentrations indicated.
Then, cells were washed (39) with 0.14 M NaCl 20 mM
Hepes, pH 7.4, followed by 4% BSA in this buffer. Cells
were ﬁxed with 4% paraformaldehyde in this buffer, and
ﬂuorescence determined and quantiﬁed with a Li-COR
Odyssey Infrared Imaging system (kEx = 785 nm;
kEm = 800 nm).
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2 9 10
6 tumor cells in phosphate-buffered saline were
injected subcutaneously into FoxN1 immunodeﬁcient
mice, and tumors were allowed to grow for 7 days. Then,
conjugates in 100 ll 0.14 M NaCl in 20 mM Hepes buffer,
pH 7.4, were injected in the tail vein under anesthesia, and
NIR ﬂuorescence visualized after different times with a Li-
COR Pearl imager (kEx = 685 and 785 nm; kEm = 702 or
789 nm). To reduce ﬂuorescence background, animals
were fed with low pheophorbide food.
Statistical analysis
Values are given as means ± standard deviations of the
mean (SD). Statistical signiﬁcance was analyzed by
ANOVA test; *P\0.05, **P\0.01, ***P\0.001.
Results
Synthesis of NIR-ﬂuorescent conjugates
IRDye800CW was selected as optical ﬂuorescence sensor
for chemokine conjugates. It proved physicochemically
stable in solution at neutral pH and yielded high ﬂuores-
cence intensity (data not shown). The N-hydroxy-succini-
mide derivative was coupled in different molecular ratios
to SDF-1 (8 kDa) at pH 8.6 and excess dye removed by gel
ﬁltration. A molar ration of 5:1 (dye:chemokine) in the
conjugation was found optimal to achieve nearly complete
conversion to the SDF-1-IRDye800CW conjugate. In
spectophotometrical analyses of the puriﬁed conjugate the
ﬁnal dye/peptide ratio was between 0.5 and 1.1. For non-
speciﬁc controls, corresponding conjugates of the chemo-
kine CXCL16 (chemokine domain 10 kDa), of lactalbumin
(14 kDa) and of BSA, (68 kDa) were synthesized. A con-
jugate of EGF was also used as a positive control for
receptor binding.
Binding properties and selectivity
of SDF-1-NIR-ﬂuorescent conjugate
Prior to binding experiments, the transcription of the
receptors for SDF-1 in endothelial and tumor cells were
compared by quantitative RT-PCR (Fig. 1a). CXCR4 was
transcribed at high rates in human umbilical vein endo-
thelial cells (HUVEC) and MCF-7 breast cancer cells,
moderately in MDA-MB-231 breast cancer, but not in
glioma (U118, U343, A764) and HT29 colon carcinoma
cells. In contrast, CXCR7 was highly transcribed in HU-
VEC, MCF-7, and glioma cells (U118, U34, A764 and
others, compare [14]), but not in MDA-MB-231 and HT29
cells. Thus, HUVEC and MCF-7 are cells with high tran-
scription of both SDF-1 receptors while glioma cells have
high transcription of only one receptor. Therefore, MCF-7
and A764 cells were selected for in vitro and in vivo
binding and functional studies.
To evaluate the sensitivity and selectivity in vitro,
increasing cell numbers were incubated for 1 h at 37C
with 100 nM SDF-1-IRDye800CW conjugate and the NIR-
ﬂuorescence measured and quantiﬁed (Fig. 1b). As few as
500 adherent cells could easily be detected. Fluorescence
increased steadily with cell number, but was not com-
pletely linear (Fig. 1c). Under the same conditions, con-
jugates (100–1,000 nM) of BSA (Fig. 1b, c), the
chemokine CXCL16 or lactalbumin (not shown) yielded
neither binding nor background. Furthermore, unlabeled
SDF-1, but not the unrelated chemokine CXCL16 nor
lactalbumin, displaced the SDF-1-conjugate dose-depen-
dently from the cells (Fig. 1c). These experiments proof a
high selectivity and a very low non-speciﬁc background of
the label in vitro.
Labeling increased with concentration and time (Fig. 1).
Time-dependency appeared saturable, but even after
15 min sufﬁcient labeling was achieved. Concentrations of
more than 10 nM SDF-1-conjugate were necessary to
achieve detectable labeling and saturation was observed
with concentrations[1000nM. An alternate conjugate of
EGF targeting the EGF receptor (EGFR) that is also
overexpressed on A764 cells bound and displaced with a
comparable afﬁnity (data not shown). Receptor-mediated
internalization of conjugates was studied in vitro with
corresponding ﬂuorescent Cy3-conjugates of SDF-1, EGF
(positive control) and BSA (negative control) in A764
glioma cells bearing the receptors CXCR7 and EGFR.
Conjugates of the bioactive peptides are found in the cells,
whereas BSA-conjugate of BSA (negative control) is not
taken up by the cells (Supplmentary Fig. 1).
Biological properties of CXCL12-NIR-ﬂuorescent
conjugate
For in vivo investigations, agonistic/antagonistic and toxic
properties have to be evaluated. Biological activities of the
ligand and conjugate were determined by analysis of the
phosphorylation of the mitogen-activated protein kinase
Erk1/2 (extracellular signal-related kinase) in A764 glioma
cells that bear only CXCR7 (Fig. 2a). Whereas native
CXCL12 induced a transient Erk1/2 phosphorylation
comparable with EGF, the conjugate did not. As a control
for loss of biological activity of the conjugate, SDF-1 was
truncated proteolytically by incubation with dipeptidyl
peptidase IV (DPP IV) liberating two N-terminal amino
acids and yielding biologically inactive SDF-1 (3–67).
Since the conjugate and also DPPIV-truncated SDF-1
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123Fig. 1 Transcription of CXCR4 and CXCR7 in different tumor and
endothelial cells and binding of NIR-ﬂuorescent ligand SDF-1-IRDye
800CW. a Transcription of the chemokine receptors in different cell
types as determined by quantitative RT-PCR; DCT values to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) are given (DCT = 3.3
corresponds to one magnitude). CXCR4 and CXCR7 are highly
transcribed both in human umbilical vein endothelial cells (HUVEC)
and in MCF-7 breast cancer cells; CXCR4 is found at moderate levels
in MDA-MB-231 breast cancer cells, but undetectable in glioma and
HT29 colon carcinoma cells; CXCR7 is also highly transcribed in
glioma cells, but not in MDA-MB-231 and HT29 cells. b Example of
NIR-ﬂuorescence labeling of tumor cells by SDF-1-IRDye 800CW.
Cultures of different numbers with A 764 glioma cells were exposed
for 1 h at 37C to 100 nM SDF-1-IRDye 800CW or the
corresponding albumin (BSA) conjugate and NIR ﬂuorescence
visualized with an Odyssey Infrared Imaging system (kEx = 785 nm,
kEm = 800 nm). As low as 500 cells can be detected by the speciﬁc
ligand; the unspeciﬁc probe yields no background even with 50,000
cells. c Quantiﬁcation of the NIR-ﬂuorescence by bound SDF-1-
IRDye 800CW and controls on A764 glioma cells: top left, cell
number dependency (100 nM, 1 h at 37C), top right, displacement of
bound SDF-1-IRDye 800CW (100 nM) by different concentrations of
native SDF-1, CXCL16 (alternate chemokine) and lactalbumin (non-
speciﬁc control; 1 h at 37C); bottom left, time-dependency of
binding (100 nM, 37C), bottom right, concentration-dependency of
SDF-1-IRDye 800CW-binding compared with EGF-IRDye 800CW
(binding to EGFR on the cells) and BSA-IRDye 800CW (non-specifc
control; all for 1 h at 37C)
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123failed to induce Erk1/2 phosphorylation, both, SDF-1-IR-
Dye800CW and SDF-1 (3–67) behaved as antagonists (on
CXCR7) which inhibited SDF-1-induced Erk 1/2 phos-
phorylation (Fig. 2b). In contrast to the SDF-1-conjugate, a
corresponding EGF-conjugate was still biologically active
(via EGFR) as with native EGF (Fig. 2c).
In further biological assays, the effects of SDF-1 and its
conjugate on cell proliferation (DNA quantiﬁcation) and
cell integrity (release of the cytosolic enzyme lactate
dehydrogenase, LDH) of A764 glioma cells were measured
(not shown). Both did not inﬂuence proliferation nor were
they cytotoxic in these assays. Thus, SDF-1-IRDye800CW
is biologically inactive and non-toxic by in vitro assays.
Visualization of tumors in vivo
In normal mice, the dye distributed rapidly through the
bodies and was nearly totally cleared within 24 h (Suppl-
mentary Fig. 2). For detection of tumors, immunodeﬁcient
nude mice were inoculated subcutaneously with two mil-
lion human MCF-7 or A764 cells, and after one week
tumors visualized by injection of 0.1 nmol SDF-1-IR-
Dye800CW (Fig. 3). After 1 h, the tumors as well as the
liver, skull and bone marrow of the hind legs were labeled
by the conjugate. After 24–92 h, background diminished
and tumors were still clearly visible. Thus, the SDF-1-
conjugate labels tumors and yields ﬂuorescence for up to
4 days. Nonspeciﬁc labeling is mainly observed in liver
and skull (probably the skin over the skull since the brain
was not labeled). Labeling of the bone marrow might be a
speciﬁc reaction, since CXCR4 is known to be expressed in
hematopoietic stem cells.
To evaluate the sensitivity and efﬁcacy of tumor label-
ing, the SDF-1-IRDye800CW conjugate was compared to
IntegriSense 680
 that targets mainly aVb3/aVb5 integrins
of the tumor vasculature (Fig. 4). In animals bearing sub-
cutaneous MCF-7 tumors both conjugates efﬁciently
labeled the tumor, but a 20-fold higher concentration of the
Integrisense
TM
680 was required (Fig. 4a). After 24 h, In-
tegriSense 680
 displayed less background in the liver than
the SDF-1-conjugate, but a little more background in lungs
and some other vascularized tissues (Fig. 4a). In mice
inoculated with MCF-7 and A764 cells at different sites,
both tumors were detected with the SDF-1-conjugate,
whereas the MCF-7 tumor was visualized only with In-
tegriSense 680
. Resection of the animals revealed vas-
cularized subcutaneous tumors of MCF-7 cells whereas
solid A764 tumors could not be recovered due to their very
small size. This shows that only vascularized solid tumors,
but not discrete tumors cells/cell aggregates can be visu-
alized by IntegriSense 680
 whereas non-vascularized
small tumors/tumor cells aggregates can be detected by
SDF-1-conjugates.
Discussion
Optical imaging of tumors by selective molecular probes
provides comparatively simple, noninvasive visualization
of tumors and their metastases. In preclinical models, such
methods can be used to monitor tumor growth, invasion,
angiogenesis and spreading and are especially applicable
for therapeutic testing. In humans, optical imaging methods
Fig. 2 Biological effects of SDF-1, epidermal growth factor (EGF)
and their NIR-ﬂuorescent conjugates. a Phosphorylation of extracel-
lular-signal regulated kinases Erk1/2 after stimulation with the
ligands (10 nM) in A764 glioma cells for different times at 37C
was determined by Western blotting with chemoluminescence
detection. Re-blots with antibody to Erk2 ensured equal loading of
the gels. SDF-1 and EGF, but not SDF-1-IRDye 800CW induced
transient Erk1/2 phosphorylation. b Antagonistic properties of SDF-1-
IRDye 800CW were ensured in corresponding experiments in which
A764 cells were stimulated (10 min, 37C) with 10 nM active SDF-1,
inactive SDF-1(3–67) obtained by proteolytic cleavage with dipep-
tidyl peptidase IV (SDF-1 ? DPP IV), SDF-1-IRDye 800CW or
combinations. The SDF-1 effects are blocked by co-incubation with
SDF-1(3–67) or SDF-1-IRDye 800CW. c In contrast to SDF-1-IRDye
800CW, the EGF-IRDye 800CW was biologically active as the native
peptide in this assay (10 nM peptide/conjugate)
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cells under surgery and control the completeness of sur-
gical resection as a principal component of current cancer
therapy. NIR ﬂuorescence-based optical imaging is a newer
imaging technique that allows sensitive detection based on
highly ﬂuorescent dyes and deep tissue penetration because
of the low absorption of light by biological tissues in the
‘‘NIR window’’ between 650–900 nm [1]. Visible light is
absorbed abundantly by tissue chromophores, in particular
hemoglobin, whereas infrared light is partly adsorbed by
water and lipids. Consequently wavelengths in the NIR
window can penetrate tissues up to a few centimeters.
Targeted probe approaches have the advantage of far better
tumor to background ratio and provide speciﬁc molecular
information that may distinguish tumors from other path-
ological alterations, mirror different stages/types of
malignancies or inform about the suitability of pharmaco-
logical therapies.
Growth factor or chemokine receptors as molecular
targets for tumor probes have the advantage that they are
directly involved in tumor growth, angiogenesis, spreading
and metastasis [19]. Among chemokines, the SDF-1–
CXCR4/7 axis is of particular importance in tumor biology.
SDF-1 is produced by mesenchymal cells in peripheral
tissues and attracts CXCR4-positive tumor cells [6]. In
addition to metastasis, SDF-1 supports paracrine tumor
growth, tumor cell invasiveness, tumor angiogenesis and
leukocyte attraction [5, 8]. The novel SDF-1 receptor,
CXCR7 and additionally CXCR4 are expressed on the
tumor vasculature and on distinct tumor cells. The bio-
logical role of CXCR7 is, however, not yet been fully
clariﬁed [9, 10, 14]. Thus, CXCR4/7-directed NIR-ﬂuo-
rescence probes label tumors at dual sites: on the tumor
endothelial cells and on some (CXCR4- and/or CXCR7-
positive) tumor cells. As a model system of tumor cells that
express either one or both receptors at high levels, we
chose MDF-7 breast cancer and A764 glioma cells.
In vitro, SDF-1-cyanine dye conjugates showed high
selectivity and sensitivity. The cyanine-dye IRDye
800CW
was chosen because of its high quantum yield, chemical and
physical stability and low toxicity [20]. A SDF-1-Cy7 con-
jugate exhibited similar biological properties, but yielded
less ﬂuorescence response (data not presented). IR-
Dye
800CW-conjugates targeting different molecules, e. g.
a EGF or 2-deoxyglucose conjugates, have been previously
prepared and effectively used to detect tumor cells in vitro
and in vivo [21, 22]. Using our SDF-1-NIR-ﬂuorescent-
conjugate we could detect as low as 500 cells in vitro.
Unrelated chemokines or non-speciﬁc (albumin) conjugates
showed no background in vitro, even at higher cell numbers
Fig. 3 Visualization of
subcutaneous tumors in mice by
injection of CXCL12-IRDye
800CW (time course). MCF-7
breast tumor and A764 glioma
cells were implanted
subcutaneously into the right
respectively left ﬂanks of
FoxN1 mice. After 6 days,
0.1 nmol SDF-1-IRDye 800CW
was injected into the tail vein
and NIR ﬂuorescence monitored
after different time with a Pearl
Imager. After 24–96 h,
subcutaneous tumors (arrows)
were good visible, but also liver,
brain and bone marrow were
labeled. Most of the non-
speciﬁc labeling diminished
after 24 h; the tumors retained
the label up to 92 h
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conjugate could be dose-dependently displaced from its
receptor by the unlabeled peptide.
In mice, the SDF-1-conjugate distributed rapidly and
then was cleared. Similar biodistribution was observed
with a
99mTc-radiolabeled SDF-1-construct in rats [23] and
with a
64Cu-radiolabeled AMD3100-conjugate [24] that
labels mainly CXCR4. After intravenous injection, a half
life of about 26 min was observed for the radiolabeled
SDF-1-conjugate, and after 2 h 74% of this label was
observed in the urine. Despite highly sensitive detection of
inﬂammatory and (metastatic) tumor cells, radioactive
SDF-1-conjugates have the clear disadvantage that they
also target tissues which are highly sensitive to radiation,
namely hematopoietic stem cells in the bone marrow,
where SDF-1 functions in recruiting homing and quies-
cence [25]. Supporting this role, in most animals our SDF-
1-IRDye
800CW conjugate labeled also bone marrow in
addition to tumors. Transient, non-speciﬁc labeling in the
ﬁrst 24 h was observed in the liver and skull.
As side effects, growth factor or chemokine conjugates
used for diagnostics can maintain tumor growth on their
own unless they target inhibitory receptors (e. g. somato-
statin receptors) or lose biological activity. In contrast to a
corresponding EGF-conjugate, our SDF-1-conjugate
showed antagonistic properties in signal transduction
assays. It is well known that small modiﬁcations of SDF-1
and other chemokines can result in loss of biological
activities while binding activity is maintained. For e.g.,
removal the two N-terminal amino acids of the 67-residue
peptide SDF-1 by the ubiquitous cell surface protease
dipeptidyl peptidase IV (DPP IV, CD26) converts it to an
antagonist [26]. Furthermore, position and type of ﬂuo-
rescent label appear to inﬂuence binding activities, at least
for short peptide analogues [27]. Synthetic CXCR4-an-
togonists like Plerixafor (AMD3100, non-peptide) or T140
(peptide) have been developed initially for the treatment of
HIV, where CXCR4 functions as a co-receptor for virus
entry into T cells. They are also under preclinical and
clinical evaluation for the treatment of leukemias/lym-
phomas, melanomas, glioblastomas, breast, small cell lung,
pancreatic, gastric and prostate cancers [8]. Consequently,
these types of tumors are well suited for imaging by SDF-
1-NIR ﬂuorescent probes. Other applications include the
Fig. 4 Comparison of the visualization of subcutaneous tumors in
mice after injection of 0.1 nmol SDF-1-IRDye 800CW and 2 nmol
IntegriSense 680
 (integrin aVb3/aVb5-targeting NIR-ﬂuorescent
dye). MCF-7 breast tumor alone or additionally A764 glioma cells
were implanted subcutaneously into FoxN1 mice. After 6 days, dyes
were injected into the tail vein and NIR ﬂuorescence monitored with a
Pearl Imager. a Visualization of different labeling intensities.
b Visualization of the two dyes at their optimal emission wavelengths
kEx = 685 nm, kEm = 702 nm for IntegriSense 680
 (as indicated),
respectively kEx = 785, kEm = 789 nm for IRDye800 CW (as
indicated), or combination. Both dyes labeled the MCF-7 tumor,
but only SDF-1-IRDye 800CW the A764 tumor cells (that were not
detectable under resection). The SDF-1 conjugate yielded sensitive
visualization even at 20-fold lower concentrations. The IntegriSense
680
 showed somewhat lower background in the liver, but higher in
the lung
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123detection of myocardial infarction [23] and chronic
inﬂammatory diseases.
In summary, NIR-ﬂuorescent conjugates of SDF-1 (and
also synthetic antagonists) show a high selectivity, speci-
ﬁcity and sensitivity in vitro and in vivo for tumor detec-
tion. In vivo, the conjugate rapidly distributes and is
cleared by the kidney. Experimental tumors are speciﬁcally
labeled, and the signals persist over days.
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